Overview

Placebo-Controlled, Double-Blind, Study to Determine the Safety and Efficacy of SDX in Patients With IH

Status:
Recruiting
Trial end date:
2024-01-30
Target enrollment:
Participant gender:
Summary
This is a study of the safety, efficacy and pharmacokinetics (PK) of Serdexmethylphenidate (SDX) compared to placebo in subjects with Idiopathic Hypersomnia (IH).
Phase:
Phase 2
Details
Lead Sponsor:
KemPharm, Inc.
Collaborator:
Rho, Inc.